A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients

Dyrberg, Eva; Hendel, Helle Westergren; Al-Farra, Gina; Balding, Lone; Løgager, Vibeke; Madsen, Claus; Thomsen, Henrik S.

doi:10.1177/2058460117738809

Cited by 11 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, more sensitive imaging techniques for the diagnosis and follow-up of MM have been described, such as WBLDCT, MRI and PET/CT. Wholebody MRI and 18F-fluorodeoxyglucose-PET/CT have been described to be more accurate in detecting bone lesions in MM as compared to skeletal surveys [8][9][10][11][12][13][14], and wholebody MRI have been found to detect significantly more MM bone involvement compared to PET/CT [12]. Whole-body MRI and PET/CT are, however, limited in their availability and are relatively costly.…”

Section: Discussionmentioning

confidence: 99%

“…However, the value of conventional radiographs in detecting osteolytic lesions is limited since at least 30% of trabecular bone must be destroyed to be visible by radiograph [7]. Cross-sectional imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and integrated positron emission tomography/CT (PET/CT), have proven to be more accurate in detecting osteolytic and marrow replacing lesions as compared to skeletal surveys using radiographs [8][9][10][11][12][13][14]. As a result, more accurate diagnosis, staging and follow-up of MM is possible [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

et al. 2019

View full text Add to dashboard Cite

Objective To evaluate organ dose and total effective dose of whole-body low-dose CT (WBLDCT) performed on different CTscanner models in patients with multiple myeloma (MM) and to compare it to the effective dose of radiographic skeletal survey and representative diagnostic CTs. Material and methods We retrospectively analyzed data from 228 patients (47.4% females, mean age 67.9 ± 10.4 years, mean weight 81.8 ± 22.4 kg) who underwent WBLDCT for the work-up or surveillance of MM. Patients were scanned using one of six multi-detector CT-scanners. Organ doses and total effective doses per scan were calculated using a commercially available dosemanagement platform (Radimetrics, Bayer Healthcare, Leverkusen, Germany). The median effective dose was compared to radiographic skeletal survey and representative diagnostic CTs. Results The mean effective dose of our WBLDCT-protocol was 4.82 mSv. A significantly higher effective dose was observed in females compared to males (4.95 vs. 4.70 mSv, P = 0.002). Mean organ dose ranged from 3.72 mSv (esophagus) to 13.09 mSv (skeleton). Mean effective dose varied amongst different CT-scanners (range 4.34-8.37 mSv). The median effective dose of WBLDCT was more than twice the dose of a skeletal survey (4.82 vs. 2.04 mSv), 23% higher than a diagnostic contrast-enhanced chest CT (3.9 mSv), 46% lower than a diagnostic contrast-enhanced abdomen/pelvis CT (9.0 mSv), and 45% lower than a lumbar spine CT (8.7 mSv). Conclusions WBLDCT in MM has a higher effective dose than a radiographic skeletal survey, but a lower effective dose than diagnostic CTs of lumbar spine, abdomen and pelvis. This underlines the broad applicability of WBLDCT in the management of MM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…18 F-sodium fluoride (NaF), a PET radiotracer which accumulates in both osteoblastic and osteolytic lesions, reflecting bone remodeling, has been investigated to a limited extent in MMBD ( 47 ). A recent small study prospectively compared SS, whole body MRI, FDG-PET-CT, and NaF-PET-CT in patients with newly diagnosed MM ( 48 ). MRI was superior to SS, FDG-PET-CT, and NaF-PET-CT.…”

Section: Imaging Techniques For Multiple Myelomamentioning

confidence: 99%

Advanced Imaging of Multiple Myeloma Bone Disease

Hansford

Silbermann

2018

Front. Endocrinol.

View full text Add to dashboard Cite

Multiple myeloma (MM), a malignancy of mature plasma cells, is the second most common hematologic malignancy and the most frequent cancer to involve the skeleton (1, 2). Bone disease in MM patients is characterized by lytic bone lesions that can result in pathologic fractures and severe pain. While recent advances in MM therapy have significantly increased the median survival of newly diagnosed patients (3), skeletal lesions and their sequelae continue to be a major source of patient morbidity and mortality and bone pain is the most frequent presenting symptom of MM patients (4). Rapid improvements in imaging technology now allow physicians to identify ever smaller skeletal and bone marrow abnormalities, however the clinical value of subtle radiographic findings is not always clear. This review summarizes currently available technologies for assessing MM bone disease and provides guidance for how to choose between imaging modalities.

show abstract

“…[6] Radiolabel PLGA nanoparticles modified with a biotinylated F-18 prosthetic group was utilized to image of their delivery to the brain by positron emission tomography (PET). [7] PLGA nanoparticles can also be used as MRI contrast agent by coating with folate, PEGylated amphiphilic octadecyl-quaternized lysinemodified chitosan (OQLCS) and paramagnetic diethylenetriaminepentaacetic acid-gadolinium (DTPA-Gd). [8] pH-sensitive PLGA-encapsulated manganese oxide (MnO) nanocrystals were successfully fabricated for molecular and cellular MRI monitoring.…”

Section: Introductionmentioning

confidence: 99%

Incorporation of Gadolinium Oxide and Gadolinium Oxysulfide Microspheres: MRI/CT Monitoring and Promotion of Osteogenic/Chondrogenic Differentiation for Bone Implants

Huang

Tang²,

Guo

et al. 2020

ChemNanoMat

View full text Add to dashboard Cite

The current biodegradable polymer materials, as orthopedic implants, can not be traced timely by using the existing medical imaging techniques due to low density and lack of relaxed hydrogen proton ability. Considering the paramagnetism of gadolinium and the particularity of micro/ nano materials, we synthesized inorganic gadolinium oxide and gadolinium oxysulfide microspheres with regular morphology and uniform size without doped rare earth. After incorporation into biodegradable polymer of poly(lactic-coglycolic acid), their effects on signals of MRI, CT and osteogenic/chondrogenic differentiation were investigated to acquisition of multifunctional micro/nano composites for bone implants. At the studied concentrations, gadolinium oxide microspheres showed higher signal than gadolinium oxysulfide microspheres on T 1-weighted imaging. Both of them were of fine biocompatibility and did not show their negative effect on adhesion and proliferation in the concentration of 0.4% (w/w, Gd/PLGA). Meanwhile, the osteogenic/ chondrogenic differentiation of MC3T3-E1 preosteoblasts, including ALP activity, calcium deposition and expression of Runx2, OPN, OCN, COL I and COL II in mRNA and protain, were stimulated at different level, which indicated that moderate use the inorganic gadolinium oxide and gadolinium oxysulfide microspheres could realize the function of tracing the polymer bone implants by MRI/CT and inducing the osteogenic/chondrogenic differentiation simultaneously.

show abstract

A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients

Cited by 11 publications

References 20 publications

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

Advanced Imaging of Multiple Myeloma Bone Disease

Incorporation of Gadolinium Oxide and Gadolinium Oxysulfide Microspheres: MRI/CT Monitoring and Promotion of Osteogenic/Chondrogenic Differentiation for Bone Implants

Contact Info

Product

Resources

About